Black Diamond Therapeutics, Inc.

BDTX Nasdaq CIK: 0001701541

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
Business Address 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE, MA, 02142
Mailing Address 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE, MA, 02142
Phone 617-417-5868
Fiscal Year End 1231
EIN 814254660

Financial Overview

FY2025

$39.35M
Total Liabilities
$116.74M
Stockholders' Equity
$0.39
EPS

Recent SEC Filings

Form Type Date Filed Document
4 Insider stock transaction report March 20, 2026 View on SEC
4 Insider stock transaction report March 20, 2026 View on SEC
10-K Annual financial report March 16, 2026 View on SEC
8-K Current report of material events March 16, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment February 17, 2026 View on SEC
4 Insider stock transaction report January 23, 2026 View on SEC
4 Insider stock transaction report January 23, 2026 View on SEC
4 Insider stock transaction report January 23, 2026 View on SEC
4 Insider stock transaction report January 23, 2026 View on SEC
4 Insider stock transaction report January 23, 2026 View on SEC

Annual Reports

10-K March 16, 2026
  • Silevertinib (BDTX-1535) successfully advanced into a Phase 2 clinical trial for recurrent or refractory glioblastoma (GBM) targeting specific EGFR activating mutations.
  • BDTX-4933, a potential treatment for EGFR-mutant non-small cell lung cancer (NSCLC), is in preclinical development with an Investigational New Drug (IND) application anticipated in 2025.
View Analysis

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.